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Abstract
Background: Dermatomyositis (DM) is inflammatory myopathy or myositis characterized by muscle weakness and skin
manifestations. In the differential diagnosis of DM the evaluation of the muscle biopsy is of importance among other
parameters. Perifascicular atrophy in the muscle biopsy is considered a hallmark of DM. However, perifascicular atrophy
is not observed in all patients with DM and, conversely, perifascicular atrophy can be observed in other myositis such
as antisynthetase syndrome (ASS), complicating DM diagnosis. Retinoic acid inducible-gene I (RIG-I), a receptor of
innate immunity that promotes type I interferon, was observed in perifascicular areas in DM. We compared the value of
RIG-I expression with perifascicular atrophy as a biomarker of DM.
Methods: We studied by immunohistochemical analysis the expression of RIG-I and the presence of perifascicular atrophy in
115 coded muscle biopsies: 44 patients with DM, 18 with myositis with overlap, 8 with ASS, 27 with non-DM inflammatory
myopathy (16 with polymyositis, 6 with inclusion body myositis, 5 with immune-mediated necrotizing myopathy), 8 with
muscular dystrophy (4 with dysferlinopathy, 4 with fascioscapulohumeral muscle dystrophy) and 10 healthy controls.
Results:We found RIG-I-positive fibers in 50% of DM samples vs 11% in non-DM samples (p< 0.001). Interestingly, RIG-I
staining identified 32% of DM patients without perifascicular atrophy (p= 0.007). RIG-I sensitivity was higher than perifascicular
atrophy (p< 0.001). No differences in specificity between perifascicular atrophy and RIG-I staining were found (92% vs 88%).
RIG-I staining was more reproducible than perifascicular atrophy (κ coefficient 0.52 vs 0.37).
Conclusions: The perifascicular pattern of RIG-I expression supports the diagnosis of DM. Of importance for clinical and
therapeutic studies, the inclusion of RIG-I in the routine pathological staining of samples in inflammatory myopathy will allow
us to gather more homogeneous subgroups of patients in terms of immunopathogenesis.
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Background
Dermatomyositis (DM) is an inflammatory myopathy
characterized by proximal muscle weakness, the presence
of perifascicular atrophy (PFA) in the muscle biopsy and
skin changes. Muscle biopsy also shows overexpression of
the major histocompatibility complex class I (MHC-I) in
the muscle fibers that is more prominent in the atrophic
perifascicular areas [1]. It has been reported that a high
percentage of patients with DM do not show PFA in the
muscle biopsy [2, 3], and conversely, patients with
antisynthetase-associated myopathy may have PFA [4, 5].
Moreover, to our knowledge the presence of PFA in the
group of overlap myositis that is included in the classifica-
tion of adult autoimmune myositis [6] has not been
explored. All these findings suggest that the diagnosis of
DM based on the presence of PFA should be made with
caution.
The role of interferons (IFN) and innate immunity in
DM is an emerging field of research [7, 8]. Type I IFN
mechanisms have been associated with DM pathogenesis
[8] and some IFN-I-induced proteins such as MxA have
been shown to be present in perifascicular muscle fibers in
DM [8]. It has been recently reported that the evaluation of
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MxA expression in the muscle biopsy is a biomarker for
DM [5]. We previously reported the overexpression of an-
other IFN-I-induced protein called retinoic acid inducible-
gene I (RIG-I, the product of the DDX58 gene) in perifasci-
cular areas in DM biopsies in five out of five patients [9].
RIG-I is a member of the RLR family of innate immune re-
ceptors that recognize dsRNA and 5′-triphosphate ssRNA
[10]. In addition, our in vitro studies using human skeletal
muscle primary cultures have shown the ability of RIG-I to
induce type I IFN responses and in turn upregulates MHC-
I and RIG-I itself [9], suggesting a specific self-sustained
pathogenic mechanism independent of inflammatory
infiltrates [11]. We aimed to determine if RIG-I staining is
a reliable diagnostic marker of DM compared with PFA in
neuromuscular diseases to validate its sensitivity and speci-
ficity using a large cohort of patients.
Methods
Patients
We collected 115 muscle biopsies performed for diagnos-
tic purposes from three hospitals in Barcelona (Sant Pau,
Vall d’Hebron, Clínic). Routine histochemical analyses
were performed. We included 44 patients with definite
DM (without criteria for any other of the clinical [4, 12]
situations mentioned subsequently), 16 with polymyositis
(PM), 6 with inclusion body myositis (IBM), 5 with
immune-mediated necrotizing myopathy (IMNM), 4 with
dysferlinopathy (Dysf), 4 with fascioscapulohumeral
muscle dystrophy (FSHD), 18 patients with various auto-
immune systemic diseases (rheumatoid arthritis (RA), sys-
temic lupus erythematosus (SLE), mixed connective tissue
disease (MCTD), systemic sclerosis (SSc) and Sjögren syn-
drome (SS)) with overlapped myopathy (OM) and 8 with
antisynthetase syndrome (ASS), who were not included in
the DM group due to recent studies that indicate its dis-
tinctiveness among the inflammatory myopathies [4, 12].
Biopsies were a representative subset of the biopsy collec-
tion that we have in each of our centers and were not se-
lected based on any specific clinical or histological feature.
As healthy controls we included 10 muscle samples from
subjects undergoing orthopedic surgery. Routine histo-
logical stains were normal. Healthy control samples were
not included in the statistical analysis.
The diagnosis of DM, PM, IBM and IMMN was based
on the ENMC criteria [13]. The diagnosis of each auto-
immune systemic disease was based on established cri-
teria [14]. Dysf and FSHD diagnosis were confirmed by
genetic analysis.
Serum autoantibodies
Anti-TIF1γ and anti-MDA5 were detected by an in-
house enzyme-linked immunosorbent assay (ELISA) and
confirmed by immunoblot [15, 16]. Other synthetases
and myositis-specific and myositis-associated antibodies
were tested using a commercial kit for myositis-antigen
profile (Euroimmun, Luebeck, Germany): anti-Mi-2,
anti-SRP, anti-Jo1, anti-Ku, anti-PM/Scl, anti-PL7, anti-
PL12, anti-EJ, anti-OJ and anti-Ro.
Immunohistochemical analysis
Immunohistochemical analysis of RIG-I and MHC-I was
performed on coded samples and the slides were read
blinded by six investigators (XSC, EG, IPF, JMG, ASO
and II). Serial sections were incubated with 3% hydrogen
peroxide (Novocastra Peroxidase Block, Novocastra
Leica Microsystems) to neutralize endogenous peroxid-
ase activity, fixed in acetone for 5 min, washed with
Tris-buffered saline (TBS) and incubated with Novocas-
tra Protein Block (Novocastra). Sections were then incu-
bated with anti-RIG-I (Thermo Scientific, Rockford,
USA) at 1/50 or with anti-MHC-I (Dako, Carpenteria,
CA, USA) at 1/100 or with anti-MxA at 1/50 (Santa
Cruz laboratories, Dallas, TX, USA) O/N at 4 °C. After
washing steps, sections were treated with Novocastra
Postprimary Block containing 10% (v/v) animal serum in
TBS. Poly-horseradish-peroxidase (HRP) anti-mouse/
rabbit IgG reagent (NovoLink Polymer) containing 10%
(v/v) animal serum in TBS was applied to localize the
primary antibody. The reaction product was visualized
by incubation with the substrate/chromogen, 3,3′-diami-
nobenzidine (DAB) prepared from Novocastra DAB
Chromogen and NovoLink DAB Substrate Buffer (Poly-
mer), as a brown precipitate, and mounted with aquatex.
Images were obtained using an Olympus BX51 micro-
scope coupled to a DP72 camera. Slides were considered
as positive when RIG-I expression was observed in at
least one row of perifascicular muscle fibers. To confirm
the specificity of RIG-I antibody, we used HEK293 cells
transfected with a RIG-I constitutive expression vector
(pCMV-RIG-I; Origene) using Fugene HD Transfection
system (Promega). Non-transfected cells were used as a
negative control (Additional file 1: Figure S1).
Analysis of perifascicular atrophy
There are no established criteria to evaluate PFA. We
performed a morphometric study measuring the mini-
mum Feret’s diameter in the muscle biopsies from pa-
tients with DM (n = 4), PM (n = 4), MCTD (n = 4) and
from controls (n = 3), stained with anti-MHC-I (Add-
itional file 2: Figure S2). We compared these objective
results with those of three independent observers asked
to assess the presence of atrophy and we obtained simi-
lar results. Muscle biopsies with PFA were considered
positive when one or more rows of perifascicular muscle
fibers had a reduction in diameter. We also analyzed the
presence of PFA using a more restrictive criterion that
included only those biopsies with two or more rows of
atrophic fibers. Therefore, the second group is included
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in the first group. Both groups were analyzed separately.
Muscle biopsies were read blinded by five independent
investigators (XSC, EG, IPF, II and NL).
Statistics
Fisher’s exact test or the chi square (χ2) test if appropriate
was used to compare RIG-I positivity between patients with
and without DM. The reproducibility of the biopsy results
between observers was assessed using Cohen’s kappa
coefficient (κ), considering a coefficient over 0.75 as excel-
lent, between 0.4 and 0.75 as fair and below 0.4 as poor.
Sensitivity and specificity of RIG-I and PFA to detect DM
were compared using the McNemar test. Statistical analyses
were performed using Stata v.13 software. A p value <0.05
was considered significant.
Results
Clinical data
All patients with myopathy included in the study had
muscle weakness evaluated by the Medical Research Coun-
cil (MRC) scale. Antibodies were tested using the Euroline
system in 41 patients with DM, 12 with PM, 6 with IBM, 5
with IMNM, 8 with ASS and 18 with OM. Anti-ARS anti-
bodies were only found in eight patients with ASS and in
one patient with OM. The antibody profiling showed the
presence of anti-Ku in 2/8 patients with OM, while all pa-
tients from the other groups tested negative (41 with DM
and 12 with PM). Reactivity against anti-PM/Scl (2/26),
anti-Jo-1 (9/26) and anti-Ro52 (6/26) were only found in
patients with ASS and OM. Anti-Mi-2 (3/41), anti-MDA5
(1/41) and anti-TIF1g (2/41) were only positive in patients
with DM. Anti-SRP antibodies were only found in one pa-
tient with IMNM. Anti-EJ, anti-OJ, anti-PL7 and anti-PL12
were negative in all the patients tested.
Perifascicular atrophy affecting two rows of muscle fibers
is more frequently associated with DM
We found that 28% of the pathological muscle biopsies in-
cluded had perifascicular muscle fibers with a reduction in
fiber diameter. In contrast, we found two or more rows of
atrophic fibers, a more restrictive criterion, in only 15% of
all pathology samples (Table 1). When we analyzed pa-
tients with DM, we found that 36% of DM samples (16/
44) displayed PFA that was restricted to 25% (11/44) when
we considered two or more rows (Table 1). In non-DM
samples we found that 21% (13/61) had PFA (7 ASS, 3
SSc, 1 Sjögren, 1 MCTD and 1 SLE sample). When we
considered two or more rows, the percentage decreased to
8% (5/61) (1 ASS, 2 SSc, 1 MCTD and 1 RA sample).
Therefore, ASS samples were significantly associated with
a single row of atrophic fibers (p < 0.001) (Table 1). Statis-
tical analysis showed that PFA was not significantly associ-
ated with DM (p = 0.089), although it was suggestive of
DM. In contrast, PFA affecting two or more rows was
significantly associated with DM (p = 0.018) (Table 2).
Perifascicular RIG-I expression is associated with DM
MHC-I overexpression was found in all DM samples as
expected (Fig. 1a) and RIG-I expression in perifascicular
areas was found with a higher frequency in DM samples
(Fig. 1b) compared to the other pathology samples. RIG-I
perifascicular expression was observed in 50% (22/44) of
Table 1 Summary of the results
Diagnosis Perifascicular atrophya Perifascicular atrophy (2 rows) RIG-I+ Total
Inflammatory myopathy (n = 71) DM 16 (36%) 11 (25%) 22 (50%) 44
PM 0 (0%) 0 (0%) 0 (0%) 16
IBM 0 (0%) 0 (0%) 2 (33%) 6
IMNM 0 (0%) 0 (0%) 0 (0%) 5
Overlapped myopathy (n = 26) ASSb 7 (88%) 1 (13%) 1 (13%) 8
RA 0 (0%) 0 (0%) 1 (50%) 2
SLE 1 (50%) 1 (50%) 1 (50%) 2
SSc 3 (60%) 2 (40%) 1 (20%) 5
Sjögren 1 (20%) 0 (0%) 0 (0%) 5
MCTD 1 (25%) 1 (25%) 1 (25%) 4
Muscle dystrophy (n = 8) Dysf 0 (0%) 0 (0%) 0 (0%) 4
FSHD 0 (0%) 0 (0%) 0 (0%) 4
Total 29 (28%) 16 (15%) 29 (28%) 105
Healthy controls were excluded from this analysis. DM dermatomyositis, PM polymyositis, IBM inclusion body myositis, IMNM immune-mediated necrotizing myopathy,
ASS anti-synthetase syndrome, RA rheumatoid arthritis, SLE systemic lupus erythematosus, SSc scleroderma and scleromyositis, MCTD mixed connective tissue disease,
Dysf dysferlinopathy, FSHD fascioscapulohumeral muscle dystrophy. aPerifasicular atrophy includes one or more rows of atrophic muscle fibers. bThe group of ASS
patients was established by the presence of anti-Jo-1 antibodies
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DM samples but not in the majority of non-DM samples
(Table 1). We only found RIG-I expression in 11% (7/61)
of non-DM samples: 1 SLE and 1 MCTD sample (both
with two or more rows of PFA) and in 1 ASS, 2 IBM, 1
RA and 1 SSc sample (none of them with PFA). Statistical
analysis demonstrated that RIG-I is significantly associated
with DM (p < 0.001) (Table 2). MHC-I overexpression was
also found in non-DM samples and in some cases, it was
restricted to one row of perifascicular atrophic fibers
(Fig. 1c) but RIG-I was negative (Fig. 1d), indicating the
usefulness of RIG-I staining.
Value of combined analysis of perifascicular atrophy and
RIG-I for the diagnosis of DM
We compared the utility of PFA (one or two or more rows
of muscle fibers) and RIG-I staining for differential diag-
nostic purposes. The specificity of PFA for DM diagnosis
based on two rows is significantly higher than considering
one row of muscle fibers (92% vs 79%: p < 0.01) (Table 2).
We did not find significant differences in sensitivity com-
paring PFA in general vs PFA restricted to two or more
rows, although we observed a clear tendency toward bet-
ter sensitivity for PFA in general (36% vs 25%; p = 0.06)
Table 2 Presence of perifascicular atrophy and RIG-I staining in the muscle biopsies of patients with DM and non-DM (1) and
sensitivity and specificity of atrophy and RIG-I positivity to diagnose DM (2)
1)
PFA#, a PFA (2 rows)b RIG-Ic
DM (N; %) 16 (36%) 11 (25%) 22 (50%)
No DM (N; %) 13 (21%) 5 (8%) 7 (11%)
p* 0.09 0.02 <0.001
2)
p (a vs b)** p (a vs c)** p (b vs c)**
Sensitivity 36% 25% 50% 0.06 0.08 0.005
Specificity 79% 92% 88% <0.01 0.08 0.7
Reproducibility (κ)*** 0.37 0.51
Healthy controls were excluded from this analysis. DM dermatomyositis, PFA perifascicular atrophy. #Perifascicular atrophy includes one or more rows of atrophic
muscle fibers. *Association between bivariate variables was perfomed using Fisher’s exact test. **Sensitivity and specificity were compared using the McNemar test.
***Reproducibility was assessed using Cohen’s kappa coefficient (κ).
Fig. 1 Representative major histocompatibility complex I (MHC-I) and RIG-I staining in serial sections of muscle biopsies. a MHC-I is expressed in
the muscle fibers from a patient with dermatomyositis (DM) displaying perifascicular atrophy. b RIG-I is expressed in perifascicular areas in the
sample from a patient with DM. c MHC-I is expressed in perifascicular atrophic areas in the sample from a patient with mixed connective tissue
disease, whereas RIG-I is not expressed (d). Original magnification × 100
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(Table 2). Perifascicular RIG-I expression showed signifi-
cantly higher sensitivity compared to the presence of two
rows of atrophic perifascicular muscle fibers (50% vs 25%;
p < 0.01), as three non-DM samples (two SSc and one ASS
sample) displayed two or more rows of atrophy but were
RIG-I-negative. In contrast, we did not find significant dif-
ferences in sensitivity comparing RIG-I with PFA in general
(50% vs 36%) (p= 0.08). We did not find significant differ-
ences in specificity comparing RIG-I with PFA (one or more
rows) (p= 0.08) and two rows of PFA (p= 0.72) (Table 2).
Interestingly, in the absence of PFA, 32% of DM samples (9/
28) had perifascicular RIG-I-positive staining, while in non-
DM samples RIG-I was observed in only 6% (3/48) (p=
0.007). We also found significant differences in RIG-I be-
tween DM and OM (50% vs 19%; p= 0.01). We compared
the reproducibility between the interpretation of RIG-I
staining and PFA. We found that RIG-I staining was more
reproducible than PFA (κ coefficient 0.51 vs 0.37). In sum-
mary, for DM diagnosis the higher sensitivity was obtained
with RIG-I expression (50%) and the higher specificity was
obtained with two or more rows of perifascicular atrophic
muscle fibers (Table 2).
Comparison of RIG-I and MxA staining
It has been shown that MxA staining in DM biopsies
can be useful as a biomarker. We analyzed MxA expres-
sion using immunohistochemical assessment in 23
muscle biopsies from our cohort (10 patients with DM,
3 with IBM, 3 with PM, 4 with OM and 3 healthy con-
trols), including patients with DM who were negative for
RIG-I, to see if the combination of both biomarkers may
improve the diagnostic power. Among the 10 patients
with DM who we analyzed, 50% were negative for both
RIG-I and MxA and did not show PFA. Two biopsies
were double-positive, one with PFA and the other with-
out PFA. Two biopsies were single-positive for RIG-I,
one with PFA and the other without PFA, and one
biopsy was single-positive for MxA, displaying PFA
(Additional file 3: Figure S3). All the patients without
DM and healthy controls were double-negative.).
Discussion
We showed that perifascicular RIG-I expression in the
muscle biopsy is a good biomarker for the diagnosis of
patients with DM. We based our conclusions on the fol-
lowing results: (1) PFA is not restricted to DM muscle
biopsies, (2) the evaluation of PFA does not always dif-
ferentiate DM from non-DM samples, (3) the evaluation
of PFA affecting two or more rows of fibers differentiates
DM from non-DM but with low sensitivity and low re-
producibility and (4) RIG-I has higher sensitivity, equiva-
lent specificity and higher reproducibility than PFA of
two or more rows of fibers. Therefore, the inclusion of
RIG-I in the panel of markers to evaluate the muscle
biopsy can also be informative in ruling out the diagno-
sis of DM in muscle biopsies from patients with overlap
syndromes showing PFA.
Perifascicular RIG-I expression was found in 50% of
patients with DM and in only 11% of patients with non-
DM, demonstrating that this marker is significantly asso-
ciated with DM (p < 0.001). In addition, RIG-I staining
had significantly higher sensitivity for DM than consid-
ering two or more rows of perifascicular atrophic fibers.
We found that 32% of DM samples that did not show
PFA were RIG-I positive. This result supports the utility
of RIG-I staining for the pathological diagnosis of DM.
We also found higher reproducibility for RIG-I staining
than for PFA. We believe that these differences in repro-
ducibility are in part due to the fact that RIG-I staining
is more easily interpretable than PFA.
PFA is considered a hallmark of DM although it is not
found in all patients with DM and is not restricted to DM,
since it may be also present in other entities such as overlap
myositis [2] or ASS [4]. The specificity of PFA was signifi-
cantly higher when considering two or more rows com-
pared to one row of perifascicular atrophic fibers (92% vs
79%). These results are probably due to the fact that most
of the samples displaying a single row of PFA corresponded
to ASS. In a study by Troyanov et al. the authors reported
that PFA can be seen as frequently in overlap myositis DM
(30%) as in pure DM (17%) [2]. In contrast, in another
study the authors found that the percentage of PFA in DM
can reach 51% [3]. Since the frequency of PFA in DM can
be variable, the need for other pathological markers for
DM is of interest. Uruha et al. recently reported the evalu-
ation of the IFN-I-induced protein MxA for DM diagnosis
[5]. They found that MxA is a valuable biomarker of DM
with high sensitivity and specificity. There are other pro-
teins that are induced by IFN-I. As the authors stated in
their study, it is necessary to evaluate other IFN-I-induced
proteins, such as RIG-I, which has been analyzed in the
present study, to find the one that is more sensitive, or the
use of a combination of different markers. In fact, our study
in a smaller group of patients showed that the combination
of both markers detected patients with DM more effi-
ciently. Although both MxA and RIG-I display good value
as biomarkers of DM, we have also evaluated overlapped
myopathies in addition to ASS, which may present with
PFA and therefore they may be included in the differential
diagnosis of DM. We indeed found that RIG-I staining is
also useful to discriminate between definite DM and over-
lapped myopathies. Along the same lines, it has been re-
ported that the distinction between the different subtypes
of inflammatory myopathies and other entities that may
share similar clinical and pathological features, such as
some types of muscular dystrophy or systemic diseases, is
very important because it implies a different prognosis and
response to therapy [1].
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Conclusions
The inclusion of biomarkers such as RIG-I in the
routine histopathological analysis of immune-mediated
myopathies will help in the definitive diagnosis of DM.
Combination of RIG-I and MxA can improve the detec-
tion of patients with DM.
Additional files
Additional file 1: Figure S1. Controls used in the study to assess the
specificity of the RIG-I antibody. RIG-I antibody was incubated in non-
transfected HEK293 cells (left) and in HEK293 cells transfected with the
constitutive expression vector pCMV-RIG-I (right). Positivity was only
observed in those cells transfected with pCMV-RIG-I. Original
magnification × 400. (TIF 3652 kb)
Additional file 2: Figure S2. Morphometric study to assess
perifascicular atrophy in muscle biopsies stained with anti-MHC-I.
Quantification of the fiber size located in the perifascicular and
intrafascicle regions in healthy controls (n = 4), and patients with DM
(n = 4), PM (n = 4) and MCTD (n = 4). A Representative images measuring
the Feret’s diameter in a healthy control (left) and in a DM (right). B The
diameter of the perifascicular fibers are significantly decreased in DM
compared to the other groups while the size of intrafascicle fibers are
not significantly different. Original magnification × 40 (upper pictures) and
digital zoom (lower pictures). (TIF 16270 kb)
Additional file 3: Figure S3. Cytoplasmatic expression of MxA in a
muscle biopsy of a patient with DM is more prominent in perifascicular
fibers. Original magnification × 100. (TIF 9388 kb)
Acknowledgements
We thank René Robles for technical support and Carolyn Newey for editorial
support.
Funding
XSC was supported by The Myositis Association (USA). This work was
supported by a grant from the Fondo de Investigaciones Sanitarias (FIS),
ISCIII and FEDER 13/0937 (II) and 15/01597 (EG) (Ministry of Health,
Spain) and by the Center for Biomedical Network Research on Rare
Diseases (CIBERER, Spain).
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
XSC performed immunohistochemical analysis, designed the study,
analyzed data and wrote the manuscript; EG designed the study,
analyzed data and wrote the manuscript; IPF designed the study,
performed statistical analysis and wrote the manuscript; NDL and MAM
participated in data analysis and helped to draft the article; CL
performed immunohistochemical analysis and analyzed data; JDM, RRJ,
IC, JMG and ASO collected samples and clinical information, analyzed
data and helped to draft the article; II designed the study, analyzed
data, collected samples and clinical information and wrote the
manuscript. All authors read and approved the manuscript.
Ethics approval and consent to participate
All patients signed an informed consent form for the use of their
muscle biopsies for research and the project was approved by the Ethics
Committee of all the hospitals involved (Comitè ètic d’investigació
clínica (CEIC)-Hospital de la Santa Creu i Sant Pau; CEIC-Hospital Clínic;
CEIC-Hospital Vall d’Hebrón) in accordance with the Declaration of
Helsinki for human research.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Neuromuscular Diseases Unit, Neurology Department, Hospital de la Santa
Creu i Sant Pau and Institut de Recerca Sant Pau, Universitat Autònoma de
Barcelona, Sant Antoni Maria Claret 167, 08025 Barcelona, Spain. 2Center for
Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain.
3Autoimmune Systemic Diseases Unit, Department of Internal Medicine,
Hospital Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
4Rheumatology Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
5Immunology Department, Hospital de La Santa Creu I Sant Pau, Universitat
Autonoma de Barcelona, Barcelona, Spain. 6Muscle Research Unit, Internal
Medicine Service, Hospital Clínic de Barcelona, Barcelona, Spain.
Received: 4 May 2017 Accepted: 6 July 2017
References
1. Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372(18):
1734–47.
2. Troyanov Y, Targoff IN, Payette MP, Raynauld JP, Chartier S, Goulet JR,
Bourre-Tessier J, Rich E, Grodzicky T, Fritzler MJ, et al. Redefining
dermatomyositis: a description of new diagnostic criteria that differentiate
pure dermatomyositis from overlap myositis with dermatomyositis features.
Medicine (Baltimore). 2014;93(24):318–32.
3. Pinal-Fernández I, Casciola-Rosen L, Christopher-Stine L, Corse A, Mammen
AL. The prevalence of individual histopathologic features varies according
to autoantibody status in muscle biopsies from dermatomyositis patients. J
Rheumatol. 2015;42(8):1448–54.
4. Aouizerate J, De Antonio M, Bassez G, Gherardi RK, Berenbaum F, Guillevin
L, Berezne A, Valeyre D, Maisonobe T, Dubourg O, et al. Myofiber HLA-DR
expression is a distinctive biomarker for antisynthetase-associated
myopathy. Acta Neuropathol Commun. 2014;2:154.
5. Uruha A, Nishikawa A, Tsuburaya RS, Hamanaka K, Kuwana M,
Watanabe Y, Suzuki S, Suzuki N, Nishino I. Sarcoplasmic MxA
expression: a valuable marker of dermatomyositis. Neurology. 2017;
88(5):493–500.
6. Senecal JL, Raynauld JP, Troyanov Y. A new classification of adult
autoimmune myositis. Arthritis Rheumatol. 2017;69(5):878–84.
7. Cappelletti C, Baggi F, Zolezzi F, Biancolini D, Beretta O, Severa M, Coccia
EM, Confalonieri P, Morandi L, Mora M, et al. Type I interferon and Toll-like
receptor expression characterizes inflammatory myopathies. Neurology.
2011;76(24):2079–88.
8. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R,
Barohn RJ, Saperstein DS, Briemberg HR, Ericsson M, et al. Interferon-alpha/
beta-mediated innate immune mechanisms in dermatomyositis. Ann
Neurol. 2005;57(5):664–78.
9. Suarez-Calvet X, Gallardo E, Nogales-Gadea G, Querol L, Navas M, Diaz-
Manera J, Rojas-Garcia R, Illa I. Altered RIG-I/DDX58-mediated innate
immunity in dermatomyositis. J Pathol. 2014;233(3):258–68.
10. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in
the host response. Nature. 2006;442(7098):39–44.
11. Greenberg SA. Sustained autoimmune mechanisms in dermatomyositis. J
Pathol. 2014;233(3):215–6.
12. Stenzel W, Preusse C, Allenbach Y, Pehl D, Junckerstorff R, Heppner FL,
Nolte K, Aronica E, Kana V, Rushing E, et al. Nuclear actin aggregation is a
hallmark of anti-synthetase syndrome-induced dysimmune myopathy.
Neurology. 2015;84(13):1346–54.
13. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR,
Vencovsky J, de Visser M, Hughes RA. 119th ENMC international workshop:
trial design in adult idiopathic inflammatory myopathies, with the exception
of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands.
Neuromuscul Disord. 2004;14(5):337–45.
14. Shoenfeld Y, Cervera R, Gershwin ME. Diagnostic criteria in autoimmune
diseases. Totowa: Humana Press; 2008.
Suárez-Calvet et al. Arthritis Research & Therapy  (2017) 19:174 Page 6 of 7
15. Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A, Trallero-Araguas E,
Balada E, Vilardell-Tarres M, Juarez C. Anti-TIF1gamma antibodies (anti-p155)
in adult patients with dermatomyositis: comparison of different diagnostic
assays. Ann Rheum Dis. 2012;71(6):993–6.
16. Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A, Trallero-Araguas E,
Balada E, Vilardell-Tarres M, Juarez C. Anti-MDA5 antibodies in a large
Mediterranean population of adults with dermatomyositis. J Immunol Res.
2014;2014:290797.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Suárez-Calvet et al. Arthritis Research & Therapy  (2017) 19:174 Page 7 of 7
